Login / Signup

Using l-Carnitine as a Pharmacologic Probe of the Interpatient and Metabolic Variability of Sepsis.

Theodore S JennaroMichael A PuskarichMarc R McCannChristopher E GilliesManjunath P PaiAlla KarnovskyCharles R EvansAlan E JonesKathleen A Stringer
Published in: Pharmacotherapy (2020)
The compiled evidence suggests there are several potential explanations for the variability in carnitine concentrations and clinical response to l-carnitine in septic shock. These serve as important confounders that should be considered in interpretation of l-carnitine clinical studies and broadly holds lessons for future clinical trial design in sepsis. Consideration of these factors is needed if precision medicine in sepsis is to be achieved.
Keyphrases
  • septic shock
  • clinical trial
  • acute kidney injury
  • intensive care unit
  • randomized controlled trial
  • current status
  • open label
  • study protocol
  • living cells
  • climate change
  • phase ii
  • single molecule